Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MGA deletion leads to Richter's transformation via modulation of mitochondrial OXPHOS

ABSTRACT: Richter’s transformation (RT) is a progression of chronic lymphocytic leukemia (CLL) to aggressive lymphoma. MGA (Max gene associated), a functional MYC suppressor, is mutated at 3% in CLL and 36% in RT. The, genetic models and molecular mechanisms of MGA deletion driving CLL to RT remain elusive. We established a RT mouse model by knockout of Mga in the Sf3b1/Mdr CLL model via CRISPR-Cas9. Murine RT cells exhibit mitochondrial aberrations with elevated oxidative phosphorylation (OXPHOS). We identified Nme1 (Nucleoside diphosphate kinase) as a Mga target through RNA sequencing and functional characterization, which drives RT by modulating OXPHOS. As NME1 is also a known MYC target without targetable compounds, we found that concurrent inhibition of MYC and ETC complex II significantly prolongs the survival of RT mice in vivo. Our results suggest that Mga-Nme1 axis drives murine CLL-to-RT transition via modulating OXPHOS, highlighting a novel therapeutic avenue for RT.

ORGANISM(S): Mus musculus

PROVIDER: GSE263238 | GEO | 2024/06/27

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Dissection of Richter’s syndrome pathogenesis and treatment through multiplexed CRISPR-based mouse models

Project description:Richter’s syndrome (RS) is a major obstacle to the management of patients with chronic lymphocytic leukemia (CLL). Its pathogenesis remains largely unknown, and presently, faithful cellular and mouse models are lacking. We report a novel congenic mouse model of RS, based on CRISPR-mediated introduction of multiplexed CLL loss-of-function lesions (i.e. Atm, Trp53, Samhd1, Mga, Birc3, Chd2) into del(13q) B cells, leading to recapitulation of disease features from CLL to transformation to RS, and exhibiting remarkable molecular and phenotypic similarity to human disease. By integrative genomic and functional analyses, we determine that mutation in Trp53, combined with Mga and Chd2, are necessary for RS transformation and for the dysregulation of E2F/MYC and interferon signaling pathways. We demonstrate that RS requires tonic PI3K signaling for survival, and shows vulnerability to MYC, CDK, mTOR and PI3K inhibitors. This model system presents a unique tool for the study of RS biology and therapy.

2022-12-05 | GSE186137 | GEO

PRMT5 Promotes Progression of Chronic Lymphocytic Leukemia [ATAC-Seq]

Project description:Purpose: Richter’s Transformation (RT) is a poorly understood and often fatal progression of chronic lymphocytic leukemia (CLL) manifesting histologically as diffuse large B-cell lymphoma. PRMT5 is implicated in lymphomagenesis, but its role in CLL or RT progression is unknown. We demonstrate herein that tumors uniformly overexpress PRMT5 in patients with progression to RT. Furthermore, mice with B-specific overexpression of hPRMT5 developed a B-lymphoid expansion with increased risk of death, and Eµ-PRMT5/TCL1 double transgenic mice uniformly developed a highly aggressive disease that histologically resembles RT; where large-scale transcriptional profiling identified unique oncogenic pathways that mediate PRMT5-driven disease progression. Taken together, the discovery that PRMT5 drives oncogenic pathways promoting RT provides a compelling rationale for clinical investigation of PRMT5 inhibitors such as PRT382 in aggressive CLL/RT cases

2022-12-07 | GSE183429 | GEO

PRMT5 Promotes Progression of Chronic Lymphocytic Leukemia [3_vs_6_mo_RNA-Seq]

2022-12-07 | GSE183427 | GEO

PRMT5 Promotes Progression of Chronic Lymphocytic Leukemia [scRNA-seq and scVDJ-seq]

2022-12-07 | GSE205704 | GEO

PRMT5 Promotes Progression of Chronic Lymphocytic Leukemia [scRNA-Seq]

2022-12-07 | GSE183426 | GEO

PRMT5 Promotes Progression of Chronic Lymphocytic Leukemia [bulk low-input RNA-Seq]

2022-12-07 | GSE183425 | GEO

CLL loss-of-function lesions distinctly impact B cell developmental and survival trajectories in B-cell restricted mouse models

Project description:Mouse models represent invaluable tools for the systematic evaluation of cancer drivers, yet those that address the impact of putative genetic drivers of chronic lymphocytic leukemia (CLL) on B cell development and function are largely lacking. To study recurrent loss-of-function (LOF) mutations observed in human CLL, we established a robust transplant model that can rapidly evaluate genetic lesions, based on CRISPR-Cas9–mediated gene knockout restricted to B cells. Using this system, we successfully generated six LOF-expressing models with B cell-specific depletion of Atm, Birc3, Trp53, Chd2, Samhd1 or Mga genes. Transcriptomic analyses identified presence of shared transcriptional networks associated with presence of the 6 modeled LOF mutations, related to increased B cell fitness in vitro and in vivo. We further identified a unique role for Mga in modulating B cell development through dysregulation of MYC and NOTCH signaling targets. None of the individual lesions led to CLL development, after 24 months of observation, supporting the relevance of combinatorial mutations for CLL development in vivo.

2022-12-05 | GSE197061 | GEO

MGA deletion leads to Richter's transformation via modulation of mitochondrial OXPHOS

Project description:MGA deletion leads to Richter's transformation via modulation of mitochondrial OXPHOS

| PRJNA1096330 | ENA

High-Resolution Genomic Profiling of Chronic Lymphocytic Leukemia Reveals New Recurrent Genomic Alterations

Project description:To identify genomic alterations in chronic lymphocytic leukemia (CLL), we performed single-nucleotide polymorphism (SNP)-array analysis on 353 samples from previously untreated patients entered on the CLL8 treatment trial. Based on paired-sample analysis (n=147), a mean of 1.8 copy number alterations (CNAs) per case were identified; about 60% of cases carried no CNAs other than those detected by routine fluorescence in-situ hybridization analysis. Copy-neutral loss-of- heterozygosity was detected in 6% of cases, and most frequently found on 13q, 17p and 11q. Minimal deleted regions (MDRs) were refined on 13q14 (deleted in 61% of cases) to the DLEU1 and DLEU2 genes, on 11q22.3 (27%) to ATM, on 2p (gained in 7% of cases) to a 1.9 Mb fragment containing 9 genes, and on 8q24 (5%) to a segment 486 Kb proximal of the MYC locus. 13q deletions exhibited proximal and distal breakpoint cluster regions. Among the most common novel lesions were deletions at 15q15.1 (4%), with the smallest deletion (70.5 Kb) found in the MGA locus; sequence analysis of MGA in 59 samples revealed a truncating mutation in one case lacking a 15q deletion. MNT at 17p13.3, which in addition to MGA and MYC encodes for the network of MAX-interacting proteins, was also found recurrently deleted. Affymetrix SNP arrays were performed according to the manufacturer's directions on DNA extracted from cryopreserved diagnostic peripheral blood samples. Copy number analysis of AffymetrixÂ® performed for 353 CLL samples. There are also 147 samples from mononuclear cells negative for CD19, which were used as references for copy number inference.

2012-10-11 | E-GEOD-36908 | biostudies-arrayexpress

RNA-seq analysis of Chronic Lymphocytic Leukemia patients belonging to stereotyped subsets #6 and #8

Project description:Chronic lymphocytic leukemia (CLL) stereotyped subsets #6 and #8 include cases expressing unmutated B cell receptor immunoglobulin (BcR IG) (U-CLL). Yet, subset #6 (IGHV1-69/IGKV3-20) is less aggressive compared to subset #8 (IGHV4-39/IGKV1(D)-39) which has the highest risk for Richter’s transformation among all CLL. The underlying reasons for this divergent clinical behavior are not fully elucidated. To gain insight into this issue, here we focused on their gene expression profiling and performed RNA-seq.

2019-04-04 | E-MTAB-6962 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data